Bharat B. Mittal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bharat B. Mittal has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Indra J. Das
Northwestern University Feinberg School of Medicine
8 shared publications - Poonam Yadav
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
6 shared publications Filippo Alongi
Università di Brescia, Direttore del Dipartimento di Radioterapia Oncologica Avanzata
3 shared publications- John A. Kalapurakal
Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
3 shared publications - Amishi Bajaj
Northwestern University, Feinberg School of Medicine
2 shared publications - Brian R. Zawislak
Department of Radiation Oncology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 East Huron Street, Galter Pavilion, LC-178, Chicago, IL 60611, USA
2 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Wiley in Head & Neck
- Vol. 48 (10) , 2821-2829
Impact of Smoking on Treatment Outcomes in Patients With Human Papillomavirus‐Related Oropharyngeal Cancer
Background: Patients with HPV+ oropharyngeal cancer (OPC) have worse outcomes with longer smoking history (≥ 10 pack‐years). This has been confirmed in trials of primary radiotherapy but not surgery, suggesting differential smoking impact by treatment received. We assessed smoking‐related outcomes at a single institution. Methods: Kaplan–Meier and Cox proportional hazards regression compared < 10 versus ≥ 10 pack‐years by treatment received for progression‐free survival (PFS) and overall survival (OS). Results: Smoking was associated with worse PFS in both primary (chemo)radiation (HR = 1.73 [1.12–2.69], p = 0.01) and primary surgery cohorts (HR = 1.77 [1.02–3.07], p = 0.04). In surgery patients, this association was attenuated after adjusting for socioeconomic indicators (HR = 1.69 [0.97–2.93], p = 0.06). On recursive partitioning analysis , ≥ 25 pack‐years was associated with worse PFS and OS overall and among radiotherapy patients. Conclusions: Smoking impacts outcomes in HPV + OPC regardless of treatment modality. Treatment‐specific differences in prior randomized studies may reflect underlying differences in patient characteristics. ≥ 25 pack‐years was associated with worse outcomes.
- 4 May 2026
- Published by Wiley in Head & Neck
- Vol. 48 (10) , 2821-2829
Open AccessImpact of Smoking on Treatment Outcomes in Patients With Human Papillomavirus‐Related Oropharyngeal Cancer
Background: Patients with HPV+ oropharyngeal cancer (OPC) have worse outcomes with longer smoking history (≥ 10 pack‐years). This has been confirmed in trials of primary radiotherapy but not surgery, suggesting differential smoking impact by treatment received. We assessed smoking‐related outcomes at a single institution. Methods: Kaplan–Meier and Cox proportional hazards regression compared < 10 versus ≥ 10 pack‐years by treatment received for progression‐free survival (PFS) and overall survival (OS). Results: Smoking was associated with worse PFS in both primary (chemo)radiation (HR = 1.73 [1.12–2.69], p = 0.01) and primary surgery cohorts (HR = 1.77 [1.02–3.07], p = 0.04). In surgery patients, this association was attenuated after adjusting for socioeconomic indicators (HR = 1.69 [0.97–2.93], p = 0.06). On recursive partitioning analysis , ≥ 25 pack‐years was associated with worse PFS and OS overall and among radiotherapy patients. Conclusions: Smoking impacts outcomes in HPV + OPC regardless of treatment modality. Treatment‐specific differences in prior randomized studies may reflect underlying differences in patient characteristics. ≥ 25 pack‐years was associated with worse outcomes.
- 21 March 2024
- Published by Springer Nature
- p. 5-20
Role of MRI in Radiation Oncology
- 21 March 2024
- Published by Springer Nature
- p. 21-33
Clinical Necessity and Patient Selection in MR-Linac
- 21 March 2024
- Published by Springer Nature
- p. 21-33
Clinical Necessity and Patient Selection in MR-Linac
- 21 March 2024
- Published by Springer Nature
- p. 1-3
Introduction to MR-Linac
- 21 March 2024
- Published by Springer Nature
- p. 469-472
Epilogue and Outlook
- Open Access
- 9 February 2024
- Published by Wiley in Journal of Skin Cancer
- Vol. 2024, 1-12
Comparative Analysis of US Guidelines for the Management of Cutaneous Squamous Cell and Basal Cell Carcinoma
Background. This study presents a comparative analysis of recently published guidelines to manage cutaneous squamous cell carcinoma (cSCC) and cutaneous basal cell carcinoma (cBCC) within the United States (US). Methods. A PubMed database search was performed for the time period between June 1, 2016, and December 1, 2022. A comprehensive comparison was performed in the following clinical interest areas: staging and risk stratification, management of primary tumor and regional nodes with curative intent, and palliative treatment. Results. Guidelines from 3 organizations were analyzed: the American Academy of Dermatology (AAD), the National Comprehensive Cancer Network (NCCN), and the American Society for Radiation Oncology (ASTRO). The guidelines used different methodologies to grade evidence, making comparison difficult. There was agreement that surgery is the preferred treatment for curative cBCC and cSCC. For patients ineligible for surgery, there was a consensus to recommend definitive radiation. AAD and NCCN recommended consideration of other topical modalities in selected low-risk cBCC. Postoperative radiation therapy (PORT) was uniformly recommended in patients with positive margins that could not be cleared with surgery and in patients with nerve invasion. The definition and extent of nerve invasion varied. All guidelines recommended surgery as the primary treatment in patients with lymph node metastases in a curative setting. The criteria used for PORT varied; NCCN and ASTRO used lymph node size, number of nodes, and extracapsular extension for recommending PORT. Both NCCN and ASTRO recommend consideration of systemic treatment along with PORT in patients with extracapsular extension. Conclusion: US guidelines provide contemporary and complementary information on the management of cBCC and cSCC. There are opportunities for research, particularly in the areas of staging, indications for adjuvant treatment in curative settings, extent of nerve invasion and prognosis, and the role of systemic treatments in curative and palliative settings.
- 9 February 2024
- Published by Wiley in Journal of Skin Cancer
- Vol. 2024, 1-12
Open AccessComparative Analysis of US Guidelines for the Management of Cutaneous Squamous Cell and Basal Cell Carcinoma
Background. This study presents a comparative analysis of recently published guidelines to manage cutaneous squamous cell carcinoma (cSCC) and cutaneous basal cell carcinoma (cBCC) within the United States (US). Methods. A PubMed database search was performed for the time period between June 1, 2016, and December 1, 2022. A comprehensive comparison was performed in the following clinical interest areas: staging and risk stratification, management of primary tumor and regional nodes with curative intent, and palliative treatment. Results. Guidelines from 3 organizations were analyzed: the American Academy of Dermatology (AAD), the National Comprehensive Cancer Network (NCCN), and the American Society for Radiation Oncology (ASTRO). The guidelines used different methodologies to grade evidence, making comparison difficult. There was agreement that surgery is the preferred treatment for curative cBCC and cSCC. For patients ineligible for surgery, there was a consensus to recommend definitive radiation. AAD and NCCN recommended consideration of other topical modalities in selected low-risk cBCC. Postoperative radiation therapy (PORT) was uniformly recommended in patients with positive margins that could not be cleared with surgery and in patients with nerve invasion. The definition and extent of nerve invasion varied. All guidelines recommended surgery as the primary treatment in patients with lymph node metastases in a curative setting. The criteria used for PORT varied; NCCN and ASTRO used lymph node size, number of nodes, and extracapsular extension for recommending PORT. Both NCCN and ASTRO recommend consideration of systemic treatment along with PORT in patients with extracapsular extension. Conclusion: US guidelines provide contemporary and complementary information on the management of cBCC and cSCC. There are opportunities for research, particularly in the areas of staging, indications for adjuvant treatment in curative settings, extent of nerve invasion and prognosis, and the role of systemic treatments in curative and palliative settings.
- Open Access
- 24 March 2023
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 4 (5) , e185-e186
Inclusion of epigenetic age acceleration in oncological trials
- 24 March 2023
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 4 (5) , e185-e186
Open AccessInclusion of epigenetic age acceleration in oncological trials
- Open Access
- 31 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (17) , 5136
Emergence of MR-Linac in Radiation Oncology: Successes and Challenges of Riding on the MRgRT Bandwagon
The special issue of JCM on “Advances of MRI in Radiation Oncology” provides a unique forum for scientific literature related to MR imaging in radiation oncology. This issue covered many aspects, such as MR technology, motion management, economics, soft-tissue–air interface issues, and disease sites such as the pancreas, spine, sarcoma, prostate, head and neck, and rectum from both camps—the Unity and MRIdian systems. This paper provides additional information on the success and challenges of the two systems. A challenging aspect of this technology is low throughput and the monumental task of education and training that hinders its use for the majority of therapy centers. Additionally, the cost of this technology is too high for most institutions, and hence widespread use is still limited. This article highlights some of the difficulties and how to resolve them.
- 31 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (17) , 5136
Open AccessEmergence of MR-Linac in Radiation Oncology: Successes and Challenges of Riding on the MRgRT Bandwagon
The special issue of JCM on “Advances of MRI in Radiation Oncology” provides a unique forum for scientific literature related to MR imaging in radiation oncology. This issue covered many aspects, such as MR technology, motion management, economics, soft-tissue–air interface issues, and disease sites such as the pancreas, spine, sarcoma, prostate, head and neck, and rectum from both camps—the Unity and MRIdian systems. This paper provides additional information on the success and challenges of the two systems. A challenging aspect of this technology is low throughput and the monumental task of education and training that hinders its use for the majority of therapy centers. Additionally, the cost of this technology is too high for most institutions, and hence widespread use is still limited. This article highlights some of the difficulties and how to resolve them.
- Open Access
- 3 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (5) , 1388
Magnetic Resonance Guided Radiotherapy for Head and Neck Cancers
Radiotherapy is an integral component of head/neck squamous cell carcinomas (HNSCCs) treatment, and technological developments including advances in image-guided radiotherapy over the past decades have offered improvements in the technical treatment of these cancers. Integration of magnetic resonance imaging (MRI) into image guidance through the development of MR-guided radiotherapy (MRgRT) offers further potential for refinement of the techniques by which HNSCCs are treated. This article provides an overview of the literature supporting the current use of MRgRT for HNSCC, challenges with its use, and developing research areas.
- 3 March 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (5) , 1388
Open AccessMagnetic Resonance Guided Radiotherapy for Head and Neck Cancers
Radiotherapy is an integral component of head/neck squamous cell carcinomas (HNSCCs) treatment, and technological developments including advances in image-guided radiotherapy over the past decades have offered improvements in the technical treatment of these cancers. Integration of magnetic resonance imaging (MRI) into image guidance through the development of MR-guided radiotherapy (MRgRT) offers further potential for refinement of the techniques by which HNSCCs are treated. This article provides an overview of the literature supporting the current use of MRgRT for HNSCC, challenges with its use, and developing research areas.
- 7 October 2021
- Published by Wiley in Head & Neck
- Vol. 43 (12) , 3955-3965
Evaluating dysphagia and xerostomia outcomes following transoral robotic surgery for patients with oropharyngeal cancer
Background: We assessed long‐term patient‐reported dysphagia and xerostomia outcomes following definitive surgical management with transoral robotic surgery (TORS) in patients with oropharyngeal cancer (OPC) via a cross‐sectional survey study.Methods: Patients with OPC managed with primary oropharyngeal surgery as definitive treatment at least 1 year ago between 2015 and 2019 were identified. The M. D. Anderson Dysphagia Inventory (MDADI) and Xerostomia Inventory (XI) scores were compared across treatment types (i.e., no adjuvant therapy [TORS‐A] vs. adjuvant radiotherapy [TORS+RT] vs. adjuvant chemoradiotherapy [TORS+CT/RT]).Results: The sample had 62 patients (10 TORS‐A, 30 TORS+RT, 22 TORS+CT/RT). TORS‐A had clinically and statistically significantly better MDADI scores than TORS+RT (p = 0.03) and TORS+CT/RT (p = 0.02), but TORS+RT and TORS+CT/RT were not significantly different. TORS‐A had clinically and statistically significantly less XI than TORS+RT (p < 0.01) and TORS+CT/RT (p < 0.01).Conclusions: Patients with OPC who have undergone TORS+RT or TORS+CT/RT following surgery face clinically worse dysphagia and xerostomia outcomes relative to patients who undergo TORS‐A.
- 7 October 2021
- Published by Wiley in Head & Neck
- Vol. 43 (12) , 3955-3965
Evaluating dysphagia and xerostomia outcomes following transoral robotic surgery for patients with oropharyngeal cancer
Background: We assessed long‐term patient‐reported dysphagia and xerostomia outcomes following definitive surgical management with transoral robotic surgery (TORS) in patients with oropharyngeal cancer (OPC) via a cross‐sectional survey study.Methods: Patients with OPC managed with primary oropharyngeal surgery as definitive treatment at least 1 year ago between 2015 and 2019 were identified. The M. D. Anderson Dysphagia Inventory (MDADI) and Xerostomia Inventory (XI) scores were compared across treatment types (i.e., no adjuvant therapy [TORS‐A] vs. adjuvant radiotherapy [TORS+RT] vs. adjuvant chemoradiotherapy [TORS+CT/RT]).Results: The sample had 62 patients (10 TORS‐A, 30 TORS+RT, 22 TORS+CT/RT). TORS‐A had clinically and statistically significantly better MDADI scores than TORS+RT (p = 0.03) and TORS+CT/RT (p = 0.02), but TORS+RT and TORS+CT/RT were not significantly different. TORS‐A had clinically and statistically significantly less XI than TORS+RT (p < 0.01) and TORS+CT/RT (p < 0.01).Conclusions: Patients with OPC who have undergone TORS+RT or TORS+CT/RT following surgery face clinically worse dysphagia and xerostomia outcomes relative to patients who undergo TORS‐A.